CYP-associated drug–drug interactions : a mission accomplished?
|Author:||Pelkonen, Olavi1; Hakkola, Jukka1,2,3; Hukkanen, Janne2,4;|
1Research Unit of Biomedicine, Pharmacology and Toxicology, University of Oulu
2Biocenter Oulu, University of Oulu
3Medical Research Center Oulu, University of Oulu and Oulu University Hospital
4Research Unit of Internal Medicine, Medical Research Center Oulu, University of Oulu and Oulu University Hospital
5Administration Center, Medical Research Center Oulu, University of Oulu and Oulu University Hospital
|Online Access:||PDF Full Text (PDF, 0.3 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2020113098699
|Publish Date:|| 2021-10-06
On the basis of official Finnish Medicines Authority (Fimea)-approved drug monographs, less than half of the approved small-molecule drugs between 2007 and 2016 were substrates, inhibitors or inducers of CYP enzymes, predominantly of CYP3A4. No significant unexpected, life-threatening, CYP-associated drug-drug interactions (CYP-DDIs) of newly approved drug entities have been observed in the last 10–15 years. The present analysis seems to suggest that tools to study and predict potentially significant CYP-DDIs are working and efficient.
Archives of toxicology
|Pages:||3931 - 3934|
|Type of Publication:||
B1 Journal article
|Field of Science:||
3121 General medicine, internal medicine and other clinical medicine
© Springer-Verlag GmbH Germany, part of Springer Nature 2020. This is a post-peer-review, pre-copyedit version of an article published in Arch Toxicol. The final authenticated version is available online at https://doi.org/10.1007/s00204-020-02912-1.